Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
A judge has refused to temporarily block California’s ban on pay-for-delay deals while a group of generics manufacturers appeal against the judge’s earlier decision.   13 January 2020
Big Pharma
Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.   10 January 2020
Americas
Senju Pharmaceutical and Bausch Health have reached an “amicable settlement” to its patent suit against Aurobindo over generic Prolensa eye drops, court filings confirm.   9 January 2020
Americas
In a partial victory for Amgen, the US Court of Appeals for the Federal Circuit concluded that a proposed generic version of Amgen’s drug Sensipar would infringe a patent earlier this week.   9 January 2020
Americas
Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.   8 January 2020
Americas
A San Diego biotechnology company has been refused a trademark registration for ‘Sequencing by Binding’ on the grounds that it is too descriptive.   8 January 2020
Americas
A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.   6 January 2020
Americas
A group of generics manufacturers yesterday, December 2 asked the US Court of Appeals for the Ninth Circuit to reverse California’s ban on pay-for-delay deals.   3 January 2020
Genetics
Gene-sequencing companies Illumina and Pacific Biosciences have “mutually agreed” to terminate their $1.2 million merger agreement, under which Illumina would have acquired PacBio.   3 January 2020
Americas
California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.   3 January 2020